1 Chloroquine diphosphate (15 mg base kg-") was given by constant rate intravenous infusion to two groups of Thai subjects. Eleven were patients with malaria (10 with Plasmodium vivax and one case with Plasmodium malariae) and 10 were healthy normal volunteers. 2 Plasma and packed red-cell concentrations of chloroquine, electrocardiographic intervals, arterial blood pressure and pulse were measured at frequent intervals.
1 Chloroquine diphosphate (15 mg base kg-") was given by constant rate intravenous infusion to two groups of Thai subjects. Eleven were patients with malaria (10 with Plasmodium vivax and one case with Plasmodium malariae) and 10 were healthy normal volunteers. 2 Plasma and packed red-cell concentrations of chloroquine, electrocardiographic intervals, arterial blood pressure and pulse were measured at frequent intervals.
3 Peak plasma concentrations at the end of the infusion ranged from 979 to 2,900 ng ml-' in the malaria patients. In the group of healthy subjects the range was 550-2,200 ng ml-'.
Values for terminal elimination rate constant, (X,) plasma clearance (CL), initial volume of distribution (V1) and volume of distribution at steady state (Vss) were calculated. For the healthy subjects, mean estimates of these parameters were X, = 0.062 ± 0.030 day-1, CL = 597 ± 238 ml min-, V1 = 0.66 ± 0.71 1 kg-" and Vss = 132 ± 50 1 kg-1
For the group of malaria patients, the corresponding values were A, = 0.055 ± 0.032 day-1, CL = 535 ± 246 ml min-1, V1 = 0.74 ± 0.75 1 kg-1 and Vss = 136 ± 64 1 kg-1
There was no statistically significant difference in the estimates for any parameter between groups (P -0.05). 4 Chloroquine concentrations in packed red blood cells consistently exceeded those in plasma and showed no consistent change with time throughout the period of study in either group. The median value for the red cell to plasma ratio was between 3 and 4 in each group. Peak red-cell concentrations were significantly higher than the equivalent plasma concentration in both groups. In the malaria patients the range of concentration was 1829-11052 ng ml-'. In the healthy volunteers, the range was 2410-4570 ng ml-'. These values Dr G. Edwards, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, L69 3BX 
Introduction Methods
Chloroquine (CQ) is the treatment of choice for malaria caused by Plasmodium vivax, malariae, ovale and sensitive strains of Plasmodium falciparum. In both healthy adults (Gustafsson et al., 1983) and children with uncomplicated falciparum malaria (Adelusi et al., 1982; Walker et al., 1983 ) the drug is well absorbed after oral administration and is detectable in the plasma for up to 52 days and in the urine for up to 119 days following oral or intravenous administration of a single dose (Gustafsson et al., 1983) . Slow, rate-controlled intravenous infusion is an acceptable mode of administration for CQ in seriously ill patients or where oral therapy is not possible Edwards et al., 1987) . Little is known about the disposition of chloroquine in this situation (White, 1985; White et al., 1987) . Studies with quinine suggest that changes in clinical condition may have profound effects on drug distribution and hence plasma and red-cell concentrations in patients with malaria (White et al., 1982) . The present study aims to compare the pharmacokinetics of CQ, given by constant-rate intravenous infusion to healthy controls and patients with Plasmodium vivax malaria.
Subjects
The study took place at Pra Pokklao Hospital, Chantaburi, Eastern Thailand and a total of twenty-one subjects participated. These numbers were calculated to be sufficient to detect changes in pharmacokinetics between malaria patients and normal subjects of the same order of magnitude as those reported for quinine in subjects with Plasmodiumfalciparum malaria (White et al., 1982 
Sampling schedule
Samples of blood were taken at the following times: before infusion, immediately after it had ceased and at the following times post-infusion; 10, 30 and 60 min, 2, 4, 6, 8, 12 , and 24 h, daily for 10 days and then for as long as possible (7-8 weeks) . Where possible, blood samples were also obtained during the period of the infusion. Haemolysis was avoided by withdrawing blood very slowly through the venous cannula. Blood (5 ml) was drawn into lithium-heparin plastic tubes and then centrifuged immediately at 1,500 g for 10 min. Plasma was removed, the buffy coat was discarded and the packed red blood cells retained. All samples were stored at -70°C prior to transport on dry-ice to Liverpool for analysis of chloroquine.
Chloroquine analysis
Plasma concentrations of chloroquine were measured by high performance liquid chromatography with fluorescence detection using a modification of the method of Alvan etal. (1982) and reported previously . To increase sensitivity at lower concentrations, the excitation wavelength was reduced from 335nm to 247nm. Metabolites of chloroquine, commonly used antimalarials and other drugs administered routinely to the patients did not interfere with the assay. Chloroquine concentrations in packed cells were measured similarly using the following method of extraction. Cells (1.0 ml) were added to a 15 ml capacity glass culture tube. To the cells were added the internal standard, 7-chloro-4-(5-diethylamino-1-methylpentylamino)-quinoline diphosphate, a gift from the Walter Reed Army Institute of Medical Research, Washington D.C., U.S.A.
(SO,u, 58.5 ng) followed by acetonitrile (2.0 ml). After vortex mixing for 15s, and centrifugation (5 min; 1,500g) the supernatant was transferred to a second 15 ml capacity glass culture tube. Ammonia (0.88 sp. gr., 2.0 ml) and n-hexane (5.0 ml) were added and the aqueous phase extracted by mechanical tumbling for 15 min. Aqueous and organic phases were separated following centrifugation (10 min, 500 g) and the aqueous phase extracted a second time according to the above procedure. The organic phases were transferred to conical glass centrifuge tubes and evaporated to dryness under a stream of nitrogen at 35°C. The residues were reconstituted in methanol (50,l) and an aliquot injected into the chromatograph. All glassware was treated with dichlorodimethylsilane (5% v/v in toluene) to minimise drug absorption.
Pharmacokinetic analysis (a) Plasma: Plasma chloroquine concentrations in the post-infusion period were analysed by a non-linear least-squares regression program (NONLIN; Metzler et al., 1973) . Equations of the general form n C(t) = Ci&e-it where C is the concentration of chloroquine in the plasma at time = t and Ci and X i are the coefficients and exponents respectively of the ith exponential term were fitted to data from each subject. The expression which contained the least number of terms but adequately described the data according to the criteria of Boxenbaum et al. (1974) was used for the evaluation of estimates of the following pharmacokinetic parameters after applying a correction to account for the length of the infusion period (Loo & Riegelman, 1970 (Gibaldi & Perrier, 1982) . A pharmacokinetic analysis was possible with ten of the volunteer subjects and nine of the malaria patients. b) Red blood cells: The ratio of the concentration of chloroquine in packed red-cells to the equivalent plasma concentration was calculated at each time point in malaria patients and 
Statistical analysis
Estimates of the pharmacokinetic parameters from the two groups were compared using a twotailed Student's t-test for either paired or unpaired observations as appropriate, accepting P <0.05 as significant.
Results

Clinical observations
There were no significant differences between the two groups of subjects in age or weight. All patients made rapid symptomatic recoveries after starting treatment. The mean (± s.d.) fever clearance time was 36.4 ± 17.2h.
Laboratory results
Admission values for biochemical, haematological and other measurements are indicated in Table 1 .
Plasma chloroquine concentrations
The inter and intra co-efficients of variation for the analysis of chloroquine in plasma and packed red blood cells were each S 10% and independent of drug concentration. Chloroquine concentrations at the end of the infusion varied between 979 and 2900 ng ml-' in the malaria patients. In the group of healthy volunteers, the range was 550-2200 ng ml-'. The mean values (± s.d.) for the two groups were 1693 ± 593 ng ml-' and 939 ± 472 ng ml-'. These values were significantly different. Chloroquine plasma concentrations declined in a multiexponential fashion in all subjects (Figure la and lb, Figure 2a and b). There were no significant differences in the estimates of X., VI or V. between healthy volunteers and malaria patients (Tables 2 and 3 ). The apparent decrease in the value for plasma clearance of chloroquine did not achieve statistical significance.
Red-cell chloroquine concentrations
Chloroquine concentrations in packed cells consistently exceeded those in plasma in both healthy volunteers and malaria patients ( Figure  la and lb, Figure 2a and b) and showed no consistent pattem of change through the period of study in either group (Figure 3a and b) . The frequency distribution curves were positively skewed with a median value between 3 and 4 in each group. Peak concentrations were significantly higher than the equivalent plasma concentrations in both groups. In the group of malaria patients, the range of values was 1829 and 11052 ng ml-'. In the group of healthy volunteers, the range was 2410-4570 ng ml-'. 
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.i n i U The mean values (± s.d.) were 3752 ± 2589 (n = five patients and one volunteer felt nauseous, 11) and 3276 ± 706 (n = 9) respectively. These one volunteer and one patient vomited and one values were not statistically significant. The volunteer complained of itching. areas (mean ± s.d.) under the packed-cell concentration vs time curves for malaria patients Cardiovascular effects Data from each group and healthy volunteers were 151637 ± 85737 ng were pooled as information from a total of only ml-1 h (n = 10) and 100053 ± 42536 ng ml-1 h fourteen subjects was available. There was a (n = 8) respectively and were not significantly small but significant fall in systolic blood presdifferent.
sure, from a resting value of 105 ± 6mm Hg to a value of 99 ± 9 mmHg 2 h after the infusion. Toxicity Systolic blood pressure had regained pre-infusion values by the time the infusion was completed Subjective effects Seven of the patients with (101 ± 10 mmHg; not significantly different malaria and six of the volunteers complained of from the resting value). There was no significant dizziness. Three patients and seven of the volun-change in measured pulse rates when baseline teers reported blurred vision during the infusion. values (77 ± 11 beats min-') and those at the end All except one patient complained of headache, of the infusion (82 ± 10 beats min-') were Cell:plasma ratio compared. When the minimum value for systolic blood pressure obtained during the infusion was compared with the baseline value for each patient using the paired t-test the differences were highly significant (P <0.0001). Likewise, if the maximum pulse measurement was compared with the resting value, a highly significant increase (P <0.01) was observed.
Electrocardiographic effects
There was a small but significant increase (9%) in PR interval when the value at the end of the infusion, 173 ± 24 ms was compared with the baseline value (158 ± 25 ms). 
Discussion
For decades chloroquine has been the mainstay of treatment for malaria throughout the world. It remains the most widely used antimalarial agent although there is considerable concern surrounding its safety when given parenterally (WHO, 1984) . Preliminary studies in volunteers (Gustafsson et al., 1983; Looareesuwan et al., 1986) showed that intravenous injection of chloroquine was potentially dangerous because of transient but very high, plasma chloroquine concentrations. It seemed likely that slow intravenous infusion of chloroquine would be safer. Until recently, the acute pharmacokinetics of intravenous chloroquine had not been investigated (White, 1985) . Before rational and safe regimens for the use of intravenous chloroquine could be devised it was essential to know the pharmacokinetics of the drug when given by slow intravenous infusion to patients with malaria. Studies had shown that malaria altered the acute pharmacokinetics of quinine so tending to increase drug concentrations even when slow intravenous infusion was used (White et al., 1982) . If disease also altered the handling of chloroquine, regimens might have to be altered to take this into account. Intramuscular injection of chloroquine to patients with malaria, although widely practised, was considered by some to be dangerous whereas slow intravenous infusion of chloroquine has generally been thought safe. Our preliminary studies in patients with falciparum malaria confirmed this but the plasma concentration profiles obtained were variable (Edwards et al., 1987) . Recently White et al. (1987) showed that slow infusion of chloroquine in Zambian patients with malaria produced therapeutic drug concentrations without serious toxicity. However, it was not clear from this work whether malaria itself altered the pharmacokinetics of the drug.
The present study shows that acute Plasmodium vivax or Plasmodium malariae malaria does not alter appreciably the plasma pharmacokinetics even when the drug is given in a relatively high therapeutic dose. Drug concentrations at the end of the 4 h infusion were above the level where toxicity might be expected and most subjects complained of some side effects. At the end of the infusion chloroquine concentrations initially declined rapidly but the drug remained detectable in plasma and packed red cells for more than 50 days. This slower decline, which reflects the large volume of distribution of chloroquine at steady state and its long elimination half-life, was not different in malaria patients as compared with controls. These findings are relevant to the optimal use of the drug in man.
When chloroquine in a dose of 3 mg of base per kg body weight was injected intravenously over 10 min to healthy volunteers, plasma drug concentrations of up to 6649 ng ml-' were achieved. Although there was no serious toxicity, all patients noticed side effects and there was a significant fall in blood pressure . The apparent initial volume of distribution (V1) derived from data obtained in that study was 0.184 ± 0.145 1 kg-' compared with a steady state value (V.s) obtained in our subjects of approximately 134 1 kg-'. This discrepancy explains the unsatisfactory plasma concentration profiles usually obtained with intravenous use in that rate of administration rather than dose size largely determines plasma concentration. Although intravenous infusion is relatively safe, (Edwards et al., 1987; our work and that of others shows that distribution is incomplete after 4 h. Longer infusion times or even continuous infusion should produce a more satisfactory profile but these would be impracticable in many hospitals in the tropics.
Acute P. vivax malaria did not appreciably alter the plasma pharmacokinetics of chloroquine. or the red cell: plasma ratio but other studies suggest that pregnancy and the more severe grades of falciparum malaria could conceivably alter chloroquine handling (White et al., 1982; Phillips et al., 1986) to a degree where regimens should be modified. Doses as high as that used in the F resent study are unnecessary; 5 mg of base kg-infused so that ?lasma concentrations do not exceed 500 ng ml should be safe and effective . Infusion times for this dose (5 mg kg-1) should be 6-8 h although this regimen should be evaluated in patients of all ages and grades of disease severity before it is accepted for routine use.
The dangers of intravenous chloroquine have been exaggerated. There is a strong suggestion in the older literature that chloroquine is superior to quinine in severe falciparum malaria (Wilson & Edeson, 1958; Scott, 1950 ). It should not be abandoned where P. falciparum remains fully sensitive to this drug and may still achieve clinical cure in areas of RI and RII resistance.
